Kymera Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. Co.'s proprietary targeted protein degradation platform, which Co. refers to as Pegasus, allows Co. to discover selective small molecule protein degraders with activity against disease-causing proteins throughout the body. Co. has utilized its Pegasus platform to design protein degraders focused in the areas of immunology-inflammation and oncology, and Co. continues to apply its platform's capabilities to additional therapeutic areas. The KYMR average annual return since 2020 is shown above.
The Average Annual Return on the KYMR average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether KYMR average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the KYMR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|